MediPharm Labs Receives Cannabis Oil Production License
BARRIE, Ontario, April 05, 2018 (GLOBE NEWSWIRE) — MediPharm Labs Inc. (“MediPharm”) is pleased to announce today that it has received its cannabis oil production license from Health Canada on March 29, 2018. This achievement is a huge milestone for MediPharm and validates the Company’s efforts over the last 30 months working tirelessly to this goal. MediPharm now takes on the bigger task of establishing itself as a leader in the cannabis concentrate field.
MediPharm is a pioneer in the cannabis industry by becoming the first company in Canada to successfully achieve a Licensed Producer approval without first receiving a cannabis cultivation license. This focus on cannabis concentrates allows MediPharm to work with its established, Health Canada approved, cultivation partners to produce pharmaceutical grade cannabis oil with a competitive advantage. This is supported by leading infrastructure in purpose built clean rooms. These ISO classified cleanrooms are designed to meet strict global cGMP regulations and support true industrial scale production.
The Health Canada license allows MediPharm to handle and manufacture cannabis oil. The license to distribute product will follow once MediPharm successfully passes the sales license criteria with Health Canada. At that time MediPharm will position itself in the cannabis industry as a business to business partner. Selling wholesale and conducting contract manufacturing will give MediPharm Labs a reach that will benefit all Canadian patients.
Located in Barrie Ontario, phase one of MediPharm’s manufacturing facility has capacity to extract over 100,000 kg of dry cannabis annually with operational space to scale up capacity with the rapid growth in the industry. The unparalleled processing expertise is instilled in the company through its executive’s roots in pharmaceuticals, bio manufacturing and healthcare delivery. MediPharm is excited to work with Canada’s current and future cultivators to uphold Canada’s reputation as global leaders in the cannabis industry.
For Additional Information Available:
Pat McCutcheon, President and CEO
investors@medipharmlabs.com
www.medipharmlabs.com
